* Rozerem sales material minimized risks - FDA
* Company says working with FDA
WASHINGTON, March 19 (Reuters) - Japan's Takeda Pharmaceutical Co 4502.T used a misleading promotion for its insomnia drug Rozerem, U.S. regulators said in a letter released on Friday.
The Food and Drug Administration said it had reviewed company sales material that “makes unsubstantiated superiority presentations, omits and minimizes the risks associated with the use of Rozerem, omits material facts, and makes a misleading claim about Rozerem.”
In a letter, the FDA said Takeda’s promotion “suggests that Rozerem has no likelihood of abuse and no toxicity, in contrast to the other 18 sedatives/hypnotics presented.”
The agency said it was not aware of substantial evidence to support that claim. Takeda spokeswoman Jocelyn Gerst said the company was working with the FDA on the matter.
The company is “working very closely with them to understand what they have raised,” she said.
The FDA posted the letterhere. (Reporting by Lisa Richwine; Editing by Ted Kerr)
Our Standards: The Thomson Reuters Trust Principles.